FDA approval of psilocybin-assisted therapy could arrive by 2027 as clinical trials, regulatory designations, and industry preparation accelerate

Psilocybin-assisted therapy could reach FDA approval by 2027 if late-stage clinical development, regulatory review, and treatment infrastructure continue moving on their current timelines. The central focus is not recreational legalization but a prescription model tied to supervised care, therapist training, manufacturing standards, and clinic readiness. Clinical trials for depression and related mental health conditions have pushed psilocybin closer to the medical mainstream, while breakthrough therapy attention and investor interest have strengthened expectations that a formal review pathway is emerging. Approval would likely depend on evidence for safety, efficacy, and durable benefit, as well as practical systems for dosing sessions, screening, and follow-up. A 2027 window matters because it frames psilocybin as a near-term healthcare issue rather than a distant cultural debate. FDA clearance would reshape mental health treatment, expand commercial and clinical activity, and intensify questions about access, cost, provider capacity, and how psychedelic care is regulated in the United States.